[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Alharbi A, Drummond D, Pinto A, Kirk V: Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy. Can Respir J; 2006 Oct;13(7):381-3
MedlinePlus Health Information. consumer health - Speech and Communication Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy.
  • Recurrent respiratory papillomatosis is a relatively uncommon disease that presents clinically with symptoms ranging from hoarseness to severe dyspnea.
  • Human papilloma virus types 6 and 11 are important in the etiology of papillomas and are most probably transmitted from mother to child during birth.
  • CO2 laser evaporation of papillomas and adjuvant drug therapy using lymphoblastoid interferon-alpha are the most common treatments.
  • However, several other treatments have been tried, with varying success.
  • [MeSH-major] Laryngeal Neoplasms / complications. Papilloma / complications. Respiratory Sounds / etiology. Speech Disorders / etiology
  • [MeSH-minor] Bronchoscopy. Chronic Disease. Combined Modality Therapy. Humans. Infant. Laser Therapy. Male. Neoplasm Recurrence, Local. Retreatment

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Aug;102(8 Pt 1):580-3 [8394667.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):532-7 [15548913.001]
  • [Cites] Laryngoscope. 1994 May;104(5 Pt 1):523-7 [8189980.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Apr;68(4):413-8 [15013606.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Dec;11(6):433-41 [14631175.001]
  • [Cites] J Virol. 1982 Oct;44(1):393-400 [6292500.001]
  • [Cites] Obstet Gynecol. 1986 Dec;68(6):795-9 [3785792.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1583-7 [12972938.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Oct;67(10):1117-21 [14550967.001]
  • (PMID = 17036092.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2683292
  •  go-up   go-down


2. Lee RG, Vecchiotti MA, Heaphy J, Panneerselvam A, Schluchter MD, Oleinick NL, Lavertu P, Alagramam KN, Arnold JE, Sprecher RC: Photodynamic therapy of cottontail rabbit papillomavirus-induced papillomas in a severe combined immunodeficient mouse xenograft system. Laryngoscope; 2010 Mar;120(3):618-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of cottontail rabbit papillomavirus-induced papillomas in a severe combined immunodeficient mouse xenograft system.
  • OBJECTIVES/HYPOTHESIS: To evaluate the efficacy of photodynamic therapy (PDT) with the phthalocyanine photosensitizer Pc 4 for treating an animal model of recurrent respiratory papillomatosis (RRP).
  • When papillomas developed, Pc 4 (0.6 or 1.0 mg/kg) was administered systemically, and 48 hours later, one papilloma of the two on each animal was exposed to 675-nm photoactivating light at either 100 or 150 J/cm(2).
  • Response was assessed by measuring papilloma size with a caliper.
  • Some papillomas and residual skin were harvested for histological assessment.
  • RESULTS: For the lower-dose PDT regimens, papilloma growth rates were not significantly different from the controls.
  • In contrast, 13 of 15 papillomas receiving the higher Pc 4 dose (1.0 mg/kg) and the higher light fluence (150 J/cm(2)) regressed completely and did not regrow within the observation period of up to 79 days.
  • The response of these papillomas was significantly different from the controls (P < .001).
  • CONCLUSIONS: Pc 4-PDT is highly effective in treating virally induced (CRPV) papillomas in a murine model of RRP, and thus warrants further study as a treatment for HPV-induced papillomas.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20091778.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA048735; United States / NCI NIH HHS / CA / R01 CA106491; United States / NCI NIH HHS / CA / P01CA48735
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Photosensitizing Agents; 0 / phthalocyanine Pc 4
  • [Other-IDs] NLM/ NIHMS695135; NLM/ PMC4459584
  •  go-up   go-down


3. Dyrstad SW, Rao KA: Recurrent Respiratory Papillomatosis (RRP)-Juvenile Onset. Clin Med Oncol; 2008;2:481-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Respiratory Papillomatosis (RRP)-Juvenile Onset.
  • In this article, we describe the treatment of long standing juvenile-onset recurrent respiratory papillomatosis (JORRP) with eventual transformation to carcinoma in a patient who lived to the age of 73.
  • Treatment modalities consisted of bronchoscopy and local excision initially.
  • Radiotherapy, chemotherapy with carboplatin (300 mg/m2) and 5-FU (600 mg/m2), oral methotrexate (5-7.5 mg/week), pegylated Interferon, indole-3-carbamide, and intralesional cidofovir were also utilized in the treatment of this patient.
  • Except for methotrexate, each of the treatment regimens used in this patient, initially decreased growth of the papillomas and improved symptoms experienced by the patient.
  • Interestingly, we found that this patient's long standing JORRP initially responded to a chemotherapy regimen of 4 cycles of carboplatin (300 mg/m2) and 5-FU (600 mg/m2) as well.
  • Ultimately, the disease became resistant to all forms of treatment and progressed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 1999 Dec;93(3):302-11 [10600342.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Jun;118(6):810-5 [9627242.001]
  • [Cites] Antivir Ther. 2002 Mar;7(1):1-9 [12008782.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):783-6 [12117334.001]
  • [Cites] Laryngoscope. 1988 Mar;98(3):334-40 [3278186.001]
  • [Cites] Laryngoscope. 1998 Jul;108(7):962-7 [9665239.001]
  • [Cites] Oncologist. 2003;8(6):508-13 [14657528.001]
  • [Cites] Head Neck. 2004 Jan;26(1):1-9 [14724900.001]
  • [Cites] Clin Diagn Lab Immunol. 2004 May;11(3):538-47 [15138179.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Feb;131(2):99-105 [15723939.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] N Engl J Med. 1988 Aug 18;319(7):401-7 [3398891.001]
  • [Cites] Head Neck. 1998 May;20(3):250-65 [9570632.001]
  • [Cites] Laryngoscope. 1998 May;108(5):735-40 [9591556.001]
  • [Cites] Head Neck. 2000 Oct;22(7):649-57 [11002318.001]
  • (PMID = 21892322.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161679
  • [Keywords] NOTNLM ; cancer / human papilloma virus / respiratory papillomatosis
  •  go-up   go-down


Advertisement
4. Palomar Asenjo V, Palomar García V, Soteras Ollé J, Ruiz Giner A: [Cidofovir activity in infantile recurrent respiratory papillomatosis]. Acta Otorrinolaringol Esp; 2005 Jan;56(1):22-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cidofovir activity in infantile recurrent respiratory papillomatosis].
  • He was diagnosed of respiratory papillomatosis.
  • In the next 10 months he underwent 6 operations to remove papillomas with CO2 laser.
  • In the last operation we decided to add adjuvant therapy with intralesional injections of cidofovir once all papillomas had been removed.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Laryngeal Neoplasms / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Laser Therapy. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747720.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


5. Hamza AH, Nasr MM, Deghady AA: The use of mitomycin-C for respiratory papillomas: clinical, histologic and biochemical correlation. Saudi Med J; 2005 Nov;26(11):1737-45
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of mitomycin-C for respiratory papillomas: clinical, histologic and biochemical correlation.
  • OBJECTIVE: To assess the clinical effects of mitomycin-C (MMC) on human papilloma virus (HPV)-infected tissues of the airway.
  • METHODS: We included 10 patients with previous histologic diagnosis of recurrent respiratory papillomas (RRP) in this prospective study, conducted at the Department of Otolaryngology-Head and Neck Surgery, University of Alexandria, Egypt, between January 2000 and December 2002.
  • Under general anesthesia, each patient underwent laser excision of all visible papillomas, followed by topical application of 1 cc of 0.5 mg/ml MMC.
  • The procedure was repeated weekly until no visible papillomas could be microscopically detected.
  • The mean serum IL-2 levels+/- SD was significantly lower in papilloma patients (83.6+/- 28.83 pg/ml) than in control subjects (196.3+/- 42.46 pg/ml) (p<0.01).
  • [MeSH-major] Mitomycin / therapeutic use. Papilloma / drug therapy. Papilloma / virology. Papillomavirus Infections / drug therapy. Respiratory Tract Neoplasms / drug therapy. Respiratory Tract Neoplasms / virology
  • [MeSH-minor] Adolescent. Base Sequence. Biopsy, Needle. Child. Child, Preschool. DNA, Viral / analysis. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laryngoscopy. Male. Molecular Sequence Data. Neoplasm Staging. Papillomaviridae / drug effects. Papillomaviridae / isolation & purification. Polymerase Chain Reaction / methods. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2006 Apr;27(4):572
  • (PMID = 16311658.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Duplicate Publication; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / DNA, Viral; 50SG953SK6 / Mitomycin
  •  go-up   go-down


6. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C: Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J; 2001 Apr;17(4):830-1
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b.
  • In contrast to uncomplicated juvenile laryngeal papillomas which may regress spontaneously, papillomatosis involving pulmonary parenchyma is associated with a poor outcome.
  • This report represents the case of a 34 yr-old female in whom respiratory papillomatosis resulted in voice problems and recurrent pneumonias due to bronchial obstruction.
  • Interferon (IFN)alpha-2b treatment was inefficient as was cidofovir monotherapy on a maintenance basis.
  • Six months of IFN-alpha-2b and cidofovir in combination led to a complete macroscopic disappearance of the laryngeal lesions and to an impressive regression of the tracheal papillomas and of the intrapulmonary consolidations.
  • These data provide support that severe respiratory papillomatosis can be safely treated by interferon alpha-2b and cidofovir in combination.
  • Probably the same mechanisms as in ribavirin plus interferon alpha-2b, in the treatment of patients with chronic hepatitis C, are responsible for the therapeutic success in this case.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Interferon-alpha / administration & dosage. Lung Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Injections, Intravenous. Laryngeal Neoplasms / drug therapy. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11401080.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 0 / Recombinant Proteins; 8J337D1HZY / Cytosine; 99210-65-8 / interferon alfa-2b; JIL713Q00N / cidofovir
  •  go-up   go-down


7. Elackattu AP, Feng L, Wang Z: A controlled safety study of diindolylmethane in the immature rat model. Laryngoscope; 2009 Sep;119(9):1803-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Diindolylmethane (DIM), a natural product from cruciferous vegetables, has been shown to be a dietary component that has inhibitory effects on some tumors (e.g., laryngeal papilloma).
  • METHODS: Forty rats were separated into four treatment groups of 10 rats each, based on the amount of study drug they received in their daily food:.
  • CONCLUSIONS: Diindolylmethane seems to have no adverse affects on the rat even when given in doses 3x what we propose to be therapeutic.
  • This adds evidence to the safety of this drug in the pediatric population as a treatment option for recurrent respiratory papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1161-72 [12479697.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 May;73(5):681-4 [19193450.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] J Toxicol Environ Health. 1987;21(3):311-23 [3495667.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):337-41 [8390800.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4569-73 [9891520.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):332-5 [15602729.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1320-7 [16385077.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4880-7 [16651444.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Sep;115(9):679-85 [17044539.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Sep;137(3):477-81 [17765779.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):661-4 [18642764.001]
  • [Cites] In Vivo. 2008 Jul-Aug;22(4):441-5 [18712169.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2619-24 [18843002.001]
  • [Cites] J Nutr. 2009 Jan;139(1):26-32 [19056653.001]
  • [Cites] J Cell Physiol. 2009 Apr;219(1):94-9 [19062173.001]
  • [Cites] Toxicol Sci. 2003 Jul;74(1):10-21 [12730619.001]
  • (PMID = 19544380.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287; United States / NIDCD NIH HHS / DC / 5R01DC008287-02; United States / NIDCD NIH HHS / DC / R01 DC008287-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / diindolylmethane; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS115765; NLM/ PMC3015182
  •  go-up   go-down


8. Major T, Sziklai I, Czeglédy J, Gáll T, Gergely L, Szarka K: Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis. Anticancer Res; 2008 Jul-Aug;28(4B):2169-74
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
  • BACKGROUND: Cidofovir is a cytosine nucleoside analogue antiviral drug given as an adjuvant therapy in recurrent respiratory papillomatosis (RRP).
  • MATERIALS AND METHODS: Intralesional cidofovir therapy was given to a 14-year-old male patient.
  • The papilloma severity score (PSS) of Derkay et al. was used for follow-up.
  • Serial fresh-frozen biopsies were taken from the lesions in the larynx and soft palate prior to therapy and during its course.
  • After human papillomavirus (HPV) typing and the determination of the genomic physical state, the HPV DNA copy number was estimated with real-time PCR.
  • RESULTS: All the papillomas harboured HPV 11 DNA in episomal form.
  • Prior to therapy, the HPV copy number fluctuated with time.
  • In the initial treatment period with 2-week-intervals both the viral load and the PSS decreased and a transient complete remission was observed.
  • CONCLUSION: The initial treatment period was successful, as the viral load decreased, and long-term effects of cidofovir might account for the controlled disease as the injection intervals were prolonged.
  • [MeSH-major] Cytosine / analogs & derivatives. DNA, Viral / genetics. Human papillomavirus 11 / genetics. Laryngeal Neoplasms / virology. Organophosphonates / therapeutic use. Papilloma / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Gene Dosage. Humans. Male. Mouth Neoplasms / drug therapy. Mouth Neoplasms / virology. Palate, Soft / pathology. Viral Load

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751391.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


9. Cullen RD, Zdanski C: Delivery of cidofovir to respiratory papillomas of the distal trachea. Laryngoscope; 2005 Mar;115(3):552-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delivery of cidofovir to respiratory papillomas of the distal trachea.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744176.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


10. Chhetri DK, Shapiro NL: A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg; 2003 Oct;129(10):1081-5
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir.
  • OBJECTIVE: To assess the efficacy of treating juvenile recurrent respiratory papillomas with intralesional cidofovir using a scheduled treatment protocol.
  • PATIENTS: Of 5 pediatric patients with recurrent respiratory papillomas, 2 had severe recurrent papillomatosis requiring long-term therapy of laser ablations every 2 weeks prior to cidofovir treatments.
  • The first 4 treatments were at 2-week intervals (week 0, 2, 4, and 6).
  • Subsequent treatment intervals were each increased by 1 week (treatments took place at week 9, 13, 18, 24, etc).
  • MAIN OUTCOME MEASURES: Papilloma stage and need for laser ablation at each scheduled visit.
  • RESULTS: The mean follow-up time was 66 weeks.
  • The mean (SD) papilloma stage decreased from 9.2 (5.5) at initial presentation to 3.4 (2.6) within 2 weeks of the first injection (P<.05), and continued to decrease for the remaining of the follow-up period.
  • Papilloma stage 0 was achieved in 4 of the 5 patients.
  • The need for laser ablation of papillomas also decreased within 4 weeks of treatment initiation (P<.05).
  • At 9 weeks, no patient required laser therapy.
  • CONCLUSION: An intralesional treatment protocol with cidofovir and increasing intervals between scheduled treatment was successful the long-term management of juvenile respiratory papillomatosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Protocols. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14568791.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


11. Peyton Shirley W, Wiatrak B: Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol; 2004 Apr;68(4):413-8
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?
  • OBJECTIVE: To assess the usefulness of cidofovir in treating recurrent respiratory papillomatosis in children.
  • Cidofovir is an acyclic nucleoside phosphonate that has been reported to be effective in the treatment of respiratory papillomatosis in several small series of patients.
  • METHODS: A prospective study was conducted in 11 children (mean, 2.1 years; range, 0.5-3 years at diagnosis) with recurrent respiratory papillomatosis who at the start of the study were requiring debridement of papillomas at least every 6 weeks.
  • After microlaryngoscopy with powered microdebridement of papillomas patients received intralesional injection of cidofovir (5mg/ml).
  • The severity of papillomatosis was rated at each visit using a standardized papilloma severity scoring system.
  • The success of therapy was measured by the trend in the patient's papilloma severity scores before and after cidofovir therapy and by whether the frequency of operative interventions decreased in the period after treatment began.
  • CONCLUSIONS: Intralesional cidofovir did not decrease the severity or frequency of operative intervention for recurrent respiratory papillomas in the majority of children in this study.
  • The drug did improve papillomatosis in the minority of patients without causing notable morbidity.
  • A large multi-institutional controlled study is needed to better assess the efficacy of this treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Organophosphonates. Organophosphorus Compounds / therapeutic use. Papilloma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Child, Preschool. Debridement. Female. Humans. Infant. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15013606.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


12. Bergler WF, Götte K: Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol; 2000;257(5):263-9
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis.
  • Juvenile-onset recurrent respiratory papillomatosis is a relatively uncommon disease that presents clinically with symptoms ranging from hoarseness to severe dyspnea.
  • Human papilloma viruses type 6 and 11 are important in the etiology of the papillomata and are most probably transmitted from mother to child during childbirth.
  • CO2 laser evaporation of papillomas and adjuvant drug therapy using lymphoblastoid alpha-interferon are the most common treatment modalities at present.
  • However, several other treatment modalities have been tried with varying success.
  • Recent advances in basic research and different therapeutic approaches are reviewed.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Papilloma / surgery. Papillomaviridae. Papillomavirus Infections / surgery. Tumor Virus Infections / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Humans. Interferon-alpha / therapeutic use. Laser Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923940.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Interferon-alpha
  • [Number-of-references] 80
  •  go-up   go-down


13. Kimberlin DW: Pharmacotherapy of recurrent respiratory papillomatosis. Expert Opin Pharmacother; 2002 Aug;3(8):1091-9
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis (RRP) is a disease which affects both children (juvenile-onset RRP) and adults (adult-onset RRP).
  • The primary management approach focuses on the removal of the papillomas by surgical debulking, although persistence of the human papillomavirus genome and subsequent recurrence of disease is the typical outcome.
  • In a minority of patients, surgical management must be supplemented with adjuvant medical therapy, with IFN being the best studied and most commonly used.
  • Other adjuvant treatments being employed include photodynamic therapy, indole-3-carbinol, ribavirin and cidofovir.
  • Large controlled trials are lacking for all but IFN, making it extremely difficult to assess clinical benefit and risk in a systematic fashion at the current time.
  • As with surgical management, viral persistence occurs following treatment with these adjuvant modalities, further contributing to the challenge of managing patients with this potentially devastating disease.
  • [MeSH-major] Antiviral Agents / therapeutic use. Laryngeal Neoplasms. Papilloma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150688.001).
  • [ISSN] 1465-6566
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 108
  •  go-up   go-down


14. Sheahan P, Sexton S, Russell JD: Is intralesional cidofovir worthwhile in juvenile recurrent respiratory papillomatosis? J Laryngol Otol; 2006 Jul;120(7):561-5
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is intralesional cidofovir worthwhile in juvenile recurrent respiratory papillomatosis?
  • OBJECTIVE: To investigate the efficacy of intralesional cidofovir in the treatment of recurrent respiratory papillomatosis (RRP) in children.
  • Surgical debulking of large papillomas was then performed, and cidofovir (5 mg/ml) injected into any remaining papillomas as well as submucosally at the sites of resected papillomas.
  • The efficacy of cidofovir was assessed by the change in papilloma severity score over the course of the treatment.
  • The greatest beneficial effect was seen after the fourth cidofovir injection; however, two patients demonstrated a deterioration in severity scores after treatment was withheld at this point.
  • CONCLUSION: Intralesional cidofovir may help control papilloma regrowth and reduce disease severity in many children with RRP.
  • There appears to be little evidence to support prolonged treatment regimes (i.e. more than eight treatments).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adjuvants, Pharmaceutic / administration & dosage. Adolescent. Child. Child, Preschool. Combined Modality Therapy / methods. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Laryngoscopy. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834805.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


15. Co J, Woo P: Serial office-based intralesional injection of cidofovir in adult-onset recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2004 Nov;113(11):859-62
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial office-based intralesional injection of cidofovir in adult-onset recurrent respiratory papillomatosis.
  • Intralesional injection of cidofovir is used in the treatment of recurrent respiratory papillomatosis as an adjuvant therapy after microsurgical excision and CO2 laser therapy.
  • We report our experience with 5 patients with adult-onset recurrent respiratory papillomatosis who were treated with intralesional injections of cidofovir after recurrence of their papillomatosis.
  • Before cidofovir injection, all patients required repeated CO2 laser treatments at intervals of less than 5 months.
  • We injected 7.5 mg/mL of cidofovir transorally into the papillomas under office telescopic control.
  • The patients were then followed up for 2 to 10 months after therapy to monitor the size of the papillomas.
  • It might be more convenient and cost-effective than performing the same procedure in the operating room with the patient under general anesthesia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15562893.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


16. Kimberlin DW, Malis DJ: Juvenile onset recurrent respiratory papillomatosis: possibilities for successful antiviral therapy. Antiviral Res; 2000 Feb;45(2):83-93
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile onset recurrent respiratory papillomatosis: possibilities for successful antiviral therapy.
  • Recurrent respiratory papillomatosis (RRP) is a potentially devastating disease that can have significant morbidity, and can even result in mortality due to airway compromise or, less commonly, malignant transformation.
  • Two distinct types of RRP exist: adult-onset RRP (AO-RRP) and juvenile-onset RRP (JO-RRP).
  • Treatment currently consists of surgical debulking of the papillomas to relieve airway obstruction.
  • However, numerous antiviral therapies have also been evaluated, albeit primarily under uncontrolled settings.
  • [MeSH-major] Antiviral Agents / therapeutic use. Laryngeal Diseases / drug therapy. Papillomaviridae. Warts / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10809017.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-15113; United States / NIAID NIH HHS / AI / N01-AI-62554
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 30
  •  go-up   go-down


17. Huber K, Sadick H, Götte K: [Current therapeutic options for recurrent respiratory papillomatosis]. HNO; 2005 Nov;53(11):921-7
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current therapeutic options for recurrent respiratory papillomatosis].
  • [Transliterated title] Aktuelle Therapieoptionen bei der rezidivierenden respiratorischen Papillomatose.
  • The purpose of this review is to describe and to critically discuss recent advances in the management of recurrent respiratory papillomatosis (RRP).
  • A curative therapy cannot be expected.
  • Literature reports an increase in adjuvant medical therapies of 10-22%.
  • The most common drugs in adjuvant therapy are interferon, cidofovir and indole-3-carbinole/diindolylmethane.
  • The lack of controlled studies limits our ability to accurately assess the antiviral action of the adjuvant therapies.
  • At the moment, therapeutic interventions remain focused on the surgical removal of papillomas when possible, and additional adjuvant therapy is available for the minority of patients for whom surgical management fails to adequately control their disease.
  • Recent advances in immunologic research offer the hope of immune system modulation as potential future treatment modalities to better control this disease process.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Otorhinolaryngologic Neoplasms / surgery. Papilloma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Child. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Drug Combinations. Follow-Up Studies. Humans. Indoles / therapeutic use. Interferons / therapeutic use. Laser Therapy. Organophosphonates / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Aug 29;325(9):613-7 [1861694.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):622-9 [14663426.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):425-8 [11926919.001]
  • [Cites] J Med Virol. 1998 Mar;54(3):219-25 [9515772.001]
  • [Cites] Obstet Gynecol. 2003 Apr;101(4):645-52 [12681865.001]
  • [Cites] Laryngoscope. 2003 Sep;113(9):1583-7 [12972938.001]
  • [Cites] Laryngoscope. 2003 Jan;113(1):139-43 [12514398.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Mar;124(3):281-7 [9525512.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(5):263-9 [10923940.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):783-6 [12117334.001]
  • [Cites] J Voice. 2004 Jun;18(2):248-53 [15193659.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Aug;102(8 Pt 1):580-3 [8394667.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Mar;113(3 Pt 1):180-6 [15053198.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Dec;11(6):433-41 [14631175.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1039-42 [15381589.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):532-7 [15548913.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Feb;112(2):197-202 [7530830.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):337-41 [8390800.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1999 Dec 5;51(2):109-13 [10619624.001]
  • [Cites] Laryngoscope. 1987 Jun;97(6):678-85 [3035299.001]
  • [Cites] Laryngoscope. 1998 Jun;108(6):935-7 [9628513.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1926-9 [12439156.001]
  • [Cites] Antiviral Res. 2004 Sep;63(3):141-51 [15451182.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 May;101(5):408-12 [1315130.001]
  • (PMID = 16142445.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Indoles; 0 / Organophosphonates; 0 / diindolylmethane; 8J337D1HZY / Cytosine; 9008-11-1 / Interferons; C11E72455F / indole-3-carbinol; JIL713Q00N / cidofovir
  • [Number-of-references] 29
  •  go-up   go-down


18. Armbruster C: Novel treatments for recurrent respiratory papillomatosis. Expert Opin Investig Drugs; 2002 Aug;11(8):1139-48
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatments for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis is a rare but often severe disease.
  • Although benign in histology, epithelial proliferations may result in progressive hoarseness, stridor, obstruction of the airway and respiratory distress.
  • The current standard of care is surgical therapy with a goal of complete removal or debulking of papillomas and preservation of normal structures.
  • Frequent recurrences and the need for repeated surgical interventions make this treatment a frustrating experience for both the patient and the physician.
  • Many adjuvant therapies have been investigated but no single treatment modality proved to be effective in eradicating recurrent respiratory papillomatosis.
  • In contrast to HIV, cytomegalovirus and hepatitis B pharmaceutical research has been less successful with human papilloma virus vaccines for a variety of reasons.
  • This review focuses on the current status of recurrent respiratory papillomatosis and on future directions of prevention and therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Papilloma / drug therapy. Papillomaviridae / drug effects. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Humans. Laser Therapy. Papillomavirus Infections / drug therapy. Papillomavirus Infections / surgery. Papillomavirus Infections / virology. Tumor Virus Infections / drug therapy. Tumor Virus Infections / surgery. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150707.001).
  • [ISSN] 1354-3784
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 85
  •  go-up   go-down


19. Limsukon A, Susanto I, Soo Hoo GW, Dubinett SM, Batra RK: Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest; 2009 Sep;136(3):924-926
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
  • Recurrent respiratory papillomatosis (RRP) can be difficult to manage.
  • Symptoms are related to recurrent tracheobronchial papillomas and are usually treated with bronchoscopic removal.
  • Other modalities are added when the papilloma burden becomes too great or recurrence is too frequent, but with limited efficacy.
  • We report a patient with progressive RRP that had become refractory to available therapy.
  • Because papillomas overexpress epidermal growth factor receptor, along with increased expression of cyclooxygenase-2 and prostaglandin E2, it was reasoned that a combination therapy of erlotinib and celecoxib would be effective in controlling papilloma growth.
  • There was a striking improvement in the number and appearance of respiratory tract papillomas, with elimination of the need for repeated papilloma removal.
  • Pretreatment and posttreatment images document this response, and the improvement has now been maintained for nearly 2 years with effective therapy.
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Laryngeal Neoplasms / drug therapy. Papilloma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Biopsy. Bronchoscopy. Celecoxib. Drug Therapy, Combination. Erlotinib Hydrochloride. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736197.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; DA87705X9K / Erlotinib Hydrochloride; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


20. Shikowitz MJ, Abramson AL, Steinberg BM, DeVoti J, Bonagura VR, Mullooly V, Nouri M, Ronn AM, Inglis A, McClay J, Freeman K: Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2005 Feb;131(2):99-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis.
  • OBJECTIVE: To determine the efficacy of photodynamic therapy (PDT) with meso-tetra (hydroxyphenyl) chlorin (m-THPC) photosensitizer for recurrent respiratory papillomatosis.
  • DESIGN: Parallel-arm, randomized trial of patients requiring surgery at least 3 times yearly with single PDT 6 or 18 months after enrollment and 12-month follow-up.
  • Disease extent was scored and papillomas were removed during direct endoscopy every 3 months after enrollment.
  • INTERVENTION: Intravenous administration of m-THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children.
  • RESULTS: There were significant differences between groups, with marked improvement in laryngeal disease across time after PDT (P = .006).
  • Five of 15 patients were in remission 12 to 15 months after treatment, but there was recurrence of disease after 3 to 5 years.
  • CONCLUSIONS: Use of m-THPC PDT reduces the severity of laryngeal papillomas, possibly through an improved immune response.
  • Failure to maintain remission with time suggests that this is not an optimal treatment.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Papilloma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723939.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / P50 DC00203
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


21. Kimberlin DW: Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res; 2004 Sep;63(3):141-51
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis.
  • HPV infections of the genital tract are of medical and public health concern due to their propensity to lead to the development of cervical cancer, and because they can be transmitted to the respiratory tract of a newborn child, resulting in juvenile-onset recurrent respiratory papillomatosis (JO-RRP).
  • The traditional treatment for JO-RRP is the physical removal of the wart through laryngoscopy and surgical debulking of the airway papillomas.
  • Papillomas frequently recur following surgical resection, however, often necessitating repeated ablative efforts to maintain a patent airway.
  • In a minority of patients, surgical management must be supplemented with adjuvant medical therapy, with interferon being the best studied and most commonly utilized.
  • Recently, a Phase II investigation of a therapeutic vaccine yielded promising results, and a Phase III evaluation of this therapeutic modality is planned.
  • Other adjuvant treatments currently being utilized, but for which controlled data of benefit are lacking, include cidofovir, indole-3-carbinol, ribavirin, mumps vaccine, and photodynamic therapy.
  • As with surgical management, viral persistence occurs following treatment with these adjuvant modalities, further contributing to the challenge of managing patients with this potentially devastating disease.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15451182.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-15113; United States / NIAID NIH HHS / AI / N01-AI62554; United States / NCRR NIH HHS / RR / RR-032
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 103
  •  go-up   go-down


22. Bielecki I, Mniszek J, Cofała M: Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol; 2009 May;73(5):681-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children.
  • INTRODUCTION: Papillomatosis of the larynx appears as the result of an infection by the human papilloma virus (HPV).
  • There is currently no effective therapy for recurrent respiratory papillomatosis (RRP).
  • The basic goal of treatment is to preserve the patency of air passages while simultaneously preserving the phonatory and anatomical functioning of the larynx.
  • Over the last 10 years, the possibility of a pharmacological treatment has been continually explored: in particular, the administration of locally passed cidofovir (first reported in a 1999 study by Pransky) to the larynx with papillomas is under current scrutiny.
  • GOAL OF STUDY: The goal of the following study is to estimate the effectiveness of locally administered cidofovir for treatment of papillomas of the larynx in children.
  • RESULTS: Seven of the 10 patients achieved total remission 6 months after the completion of treatment, scoring 0 points on Derkay's scale.
  • These patients underwent therapy with cidofovir from 6 to 13 months.
  • Three months after the completion of treatment, three children suffered a recurrence of papillomas.
  • CONCLUSIONS: The results of the study indicate that intralesional injections of cidofovir can be an effective method of treatment for recurrent respiratory papillomatosis in children.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193450.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


23. Hawkes M, Campisi P, Zafar R, Punthakee X, Dupuis A, Forte V, Ford-Jones EL: Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J; 2008 Feb;27(2):149-54
MedlinePlus Health Information. consumer health - HPV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus.
  • BACKGROUND: With the recent licensure of a new quadrivalent vaccine, many diseases caused by human papillomavirus (HPV) can now be prevented, including recurrent respiratory papillomatosis (RRP).
  • The purpose of this study was to describe the burden and time course of juvenile onset RRP.
  • Statistical methods included descriptive statistics of the cohort, a repeated events survival model, and nonlinear modeling equations to describe the time course of illness.
  • Adjuvant pharmacologic therapy (interferon or cidofovir) was used in 13 cases (19%).
  • HPV types 6 or 11 were identified most commonly as the etiologic agent.
  • Repeated events survival analysis identified significant prognostic variables: surgeon, adjuvant therapy, and anatomic score.
  • A decision rule is presented that allows the time to next surgery to be predicted based on the previous surgery and the anatomic score.
  • CONCLUSIONS: Most patients have a decelerating rate of debulking surgeries over time, well described by our nonlinear modeling equations.
  • Factors affecting the time course of RRP include: inter-surgeon variability, the extent and severity of papillomas at the time of laryngoscopy, and the use of adjuvant medical therapies.
  • [MeSH-major] Alphapapillomavirus. Papillomavirus Infections / pathology. Respiratory Tract Infections / virology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174855.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Nowaczewska K, Wójtowicz P, Kukwa A, Ratajczak J, Tulibacki M: [Respiratory papillomatosis--new methods of treatment]. Otolaryngol Pol; 2010 Jan-Feb;64(1):31-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Respiratory papillomatosis--new methods of treatment].
  • BACKGROUND: Respiratory papillomatosis is caused by HPV.
  • The aim of this study was to estimate new methods of treatment respiratory papillomatosis based on intralesional injection of cidofovir into sites where papillomas had just been excised.
  • The treatment was based on surgical excision of papilloma and after it intralesional injection of cidofovir in after 4-5 weeks.
  • 41 patients had 4 times intralesional injection of cidofovir.
  • 18 patients had increased number of injection of ciodofovir because of recurrent papilloma.
  • CONCLUSION: Surgery with intralesional cidofovir injection in the place after removal of papilloma is very effective methods.
  • We observed that this treatment caused long lasting remission of papilloma recurrence.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Poland. Remission Induction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476590.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


25. Tsvetkov EA, Sel'kov SA, Chmyreva NN: [Interferon therapy and immunotherapy in children with respiratory papillomatosis]. Vestn Otorinolaringol; 2002;(2):34-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon therapy and immunotherapy in children with respiratory papillomatosis].
  • The ENT clinic of St-Petersburg Pediatric Medical Academy for 15 years admitted 126 children with respiratory papillomatosis 10 months to 15 years of age.
  • The scheme of combined treatment was adjusted to interferon status of the patients.
  • Replacement therapy with recombinant interferon--viferon--was applied in low production of alpha/beta-interferon but high serum interferon.
  • In low serum interferon and intact interferon reserves the treatment was combined: interferon inductor--cycloferon plus viferon.
  • In all the children the above treatment was given following surgical (microendoscopic) removal of laryngeal papillomas.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents / therapeutic use. Interferon-beta / therapeutic use. Interferon-gamma / therapeutic use. Papilloma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056158.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 77238-31-4 / Interferon-beta; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


26. Pransky SM, Brewster DF, Magit AE, Kearns DB: Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2000 Oct;126(10):1239-43
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis.
  • OBJECTIVES: To continue assessment of the benefits and risks of intralesional administration of cidofovir, an acyclic nucleoside phosphonate, for treating severe recurrent respiratory papillomatosis (RRP) in pediatric patients, and to discuss guidelines for larger prospective multi-institutional studies of the use of cidofovir.
  • PATIENTS: A total of 10 patients with severe RRP (defined as requiring debulking procedures to maintain airway patency at least once a month) underwent intralesional cidofovir therapy.
  • INTERVENTION: Microsuspension laryngoscopy with intralesional injection of cidofovir after repetitive carbon dioxide laser treatments and mechanical debulking of papillomas.
  • MAIN OUTCOME MEASURES: Papilloma stage at the time of serial laryngoscopies.
  • Histologic examination of biopsy specimens of laryngeal tissue obtained 1 year or more after last cidofovir injection.
  • CONCLUSIONS: Intralesional cidofovir therapy continues to show benefit in the treatment of severe RRP in pediatric patients.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Injections, Intralesional. Male. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11031411.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


27. Milczuk HA: Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children. Otolaryngol Head Neck Surg; 2003 Jun;128(6):788-94
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children.
  • OBJECTIVE: We sought to determine the efficacy of intralesional injection of cidofovir in improving resolution of recurrent respiratory papillomatosis (RRP).
  • Cidofovir (5 mg/mL) was injected into airway sites where papillomas had just been excised using sharp technique.
  • Each patient had 6 treatments performed 6 to 8 weeks apart.
  • Biopsies confirmed benign papilloma lesions in all cases.
  • During treatment with intralesional cidofovir there was diminished growth of the papillomas in each patient.
  • Once cidofovir treatment was stopped, the rate of regrowth and frequency of surgical excision returned to pretreatment levels in 3 of the 4 patients.
  • CONCLUSIONS: Intralesional cidofovir may provide benefit in reducing the rate of RRP growth while under treatment, but RRP severity returned to pretreatment levels once cidofovir treatment was stopped using this treatment program.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage. Papilloma / drug therapy. Papillomaviridae. Papillomavirus Infections / drug therapy. Tumor Virus Infections / drug therapy

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12825028.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


28. Nagel S, Busch C, Blankenburg T, Schütte W: [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab]. Pneumologie; 2009 Jul;63(7):387-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab].
  • [Transliterated title] Behandlung der respiratorischen Papillomatose--Kasuistik zur systemischen Therapie mit Bevacizumab.
  • BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a known but rare disease, caused by human papilloma virus and characterised by multiple exophytic lesions and uncontrolled growth of papilloma in the respiratory tract.
  • Medical therapeutic options have so far been less effective.
  • However, inhibition of vascular endothelial growth factor (VEGF) by bevacizumab does appear to be an effective treatment option for RRP.
  • CASE REPORT: The case of a 32-year-old male patient with RRP who has been treated for his symptomatic tracheal stenosis four times a year since 1996 is described.
  • Only treatment by laser ablation showed any efficacy.
  • Alternative treatment options did not show any effect.
  • During this treatment no further laser ablation was necessary.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Papilloma / drug therapy. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Bevacizumab. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591084.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


29. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • INTRODUCTION: Recurrent respiratory papillomatosis (RRP) is a rare disease in children and adults.
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


30. Schraff S, Derkay CS, Burke B, Lawson L: American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg; 2004 Sep;130(9):1039-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.
  • OBJECTIVE: To evaluate how evolving treatment technologies have affected our management of recurrent respiratory papilloma (RRP) since the last comprehensive survey of pediatric otolaryngologists in 1998.
  • A total of 150 (21%) of these patients presently receive adjuvant medical therapies with cidofovir and interferon, accounting for more than two thirds of the total.
  • Distal spread of RRP has occurred in 94 (13%) of the 700 patients.
  • The laryngeal microdebrider (53%) has supplanted the carbon dioxide laser (42%) as the preferred means of surgically removing papilloma from the larynx in children.
  • Routine human papillomavirus subtyping is practiced by 45% of respondents while 15% treat all their patients with antireflux medications.
  • CONCLUSIONS: Recurrent respiratory papilloma continues to be a frustrating disease to treat and is associated with significant morbidity and mortality.
  • There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Australia. Chemotherapy, Adjuvant. Child. Child, Preschool. Debridement / methods. Europe. Health Care Surveys. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Microsurgery. North America. Organophosphorus Compounds / therapeutic use

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15381589.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


31. Szydłowski J, Cofta J, Wiktorowicz K, Grzegorowski M: [The interaction of stilbazolium merocyanines with hyperproliferative laryngeal papilloma cells--preliminary study]. Otolaryngol Pol; 2003;57(6):823-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The interaction of stilbazolium merocyanines with hyperproliferative laryngeal papilloma cells--preliminary study].
  • Recently increasing interest focused in possible clinical application on photodynamic therapy was observed.
  • Many scientists are looking for new chemical compounds effective in therapy and giving no side effects.
  • The aim of this study was to estimate the usefulness of the selected stilbazolium merocyanines to treatment on human recurrent respiratory papillomatosis.
  • Tissue samples were analyzed for presence of Human papillomavirus (HPV).
  • The incorporation of the dye into papillomas cells membranes was measured by flow cytometry.
  • The hyperplastic tissue showed the highest fluorescence intensity than normal epithelium.
  • [MeSH-major] Benzylidene Compounds / pharmacology. Dihydropyridines / pharmacology. Laryngeal Neoplasms / drug therapy. Papilloma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15049182.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Benzylidene Compounds; 0 / Dihydropyridines; 0 / stilbazolium merocyanine
  •  go-up   go-down


32. Naiman AN, Abedipour D, Ayari S, Fresnel E, Coulombeau B, Bour JB, Froehlich P: Natural history of adult-onset laryngeal papillomatosis following multiple cidofovir injections. Ann Otol Rhinol Laryngol; 2006 Mar;115(3):175-81
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: A prospective study was performed to assess the intermediate and long-term efficacy of intralesional cidofovir therapy associated with surgical excision in laryngeal papillomatosis in adults.
  • METHODS: Endoscopy with intralesional injection of cidofovir 5 mg/mL was performed 3 times at 4-week intervals.
  • Further treatment was performed at 3 or 6 months, depending on the evolution of the papillomas.
  • After complete remission, the treatment was stopped and the patients were reviewed every 6 months.
  • CONCLUSIONS: The effectiveness of intralesional cidofovir therapy in adult-onset recurrent respiratory papillomatosis was impressive.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adult. Biopsy. DNA, Viral / analysis. Female. Follow-Up Studies. Human papillomavirus 6 / genetics. Humans. Injections, Intralesional. Laryngoscopy. Male. Middle Aged. Papillomavirus Infections / drug therapy. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Prospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572605.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


33. Derkay C, Multi-Disciplinary Task Force on Recurrent Respiratory Papillomas: Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks. Int J Pediatr Otorhinolaryngol; 2005 Nov;69(11):1465-7
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinogens / administration & dosage. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papillomavirus Infections / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Animals. Child. Drug Approval. Humans. Risk Assessment. Severity of Illness Index. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174538.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Editorial; Practice Guideline
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Carcinogens; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down






Advertisement